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Abstract
Background—Patients undergoing hematopoietic stem cell transplant (HSCT) can experience 
gastrointestinal (GI) side effects as a complication of the treatment. Limited research exists 
describing how the duration and severity of GI side effects influence the consumption of adequate 
calorie intake in this population. The purpose of this study was to assess differences in GI side 
effects between patients who consumed adequate calories compared with those who did not.
Methods—The MD Anderson Symptom Inventory–Gastrointestinal (MDASI-GI) tool was used 
to record daily GI side effects of 72 HSCT patients. Daily calorie intake was determined via 
calorie counts. Data were collected from day of transplant until engraftment.
Results—Median percentage of caloric needs consumed for all patients was 49.2% (interquartile 
range, 35.1–66.6). Calorie intake decreased from baseline to transplant day 8 as severity of GI 
symptoms increased. An inverse relationship between percentage of caloric needs met and 
MDASI-GI component score, MDASI-GI symptom score, and lack of appetite score was 
observed. The only significant difference in MDASI-GI symptom scores between those who 
consumed adequate calories and those who consumed inadequate calories was for diarrhea; 
subjects who consumed >60% of caloric needs had significantly lower median diarrhea scores.
Conclusion—Most patients consumed <60% of their caloric needs from time of transplant to 
time of engraftment. More research is needed to provide insight into strategies to increase intake 
and to describe the implications of prolonged inadequate intake in HSCT patients. (Nutr Clin 
Pract. 2015;30:305–310)
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Background
Patients receiving hematopoietic stem cell transplantation (HSCT) often experience 
symptoms of treatment that impair their ability to consume adequate calories. In the past, 
patients who experienced these gastrointestinal (GI) side effects were often administered 
parenteral nutrition (PN) to help prevent a decline in their nutrition status. However, several 
studies have linked the use of PN to complications such as increased incidence of 
hyperglycemia and delayed time to engraftment.1,2 When HSCT patients are unable to 
consume or absorb an adequate amount of nutrients for extended time frames, PN may be 
essential, but its discontinuation is recommended once toxicities from treatment resolve.3 
Enteral nutrition (EN) has been shown to help minimize some of the risks associated with 
PN. While EN has been demonstrated to be safe and feasible in some HSCT populations,4,5 
routine use in all HSCT patients has been limited. The limited use of EN is most likely due 
to the lack of evidence for EN’s impact on clinical outcomes, clinicians’ concerns with 
increased potential for a higher risk of infection and bleeding associated with GI tube access, 
and effect of EN on GI toxicities. There is also limited research regarding how oral food 
consumption affects frequency and severity of GI symptom distress in HSCT patients. Many 
HSCT patients tolerate treatment without nutrition support and continue consuming an oral 
diet ad libitum. However, oral ingestion of adequate calories is often difficult for HSCT 
patients due to the many side effects experienced secondary to HSCT treatment. The 
tolerance and effectiveness of oral and/or EN in HSCT patients and the relationship between 
adequate energy and frequency, severity, and duration of GI symptoms have not been well 
reported. The purpose of this study was to assess differences in GI side effects in HSCT 
patients who consumed adequate energy intake compared with those who consumed 
inadequate energy intakes during the course of their HSCT treatment.
Materials and Methods
Patients
During the study period, 116 patients were admitted to the bone marrow transplant unit of a 
tertiary care urban academic medical center. Of those patients, 88 agreed to participate in the 
study (76%). Those who failed to consent were non–English speaking (n = 8), had 
previously participated in the study (n = 4), did not want to participate daily (n = 4), were 
too anxious (n = 2), or declined for various other miscellaneous reasons (n = 10). Of the 88 
patients who agreed to participate, 2 dropped out of the study due to personal reasons and 1 
patient did not engraft. Thirteen patients received PN at some point during time of transplant 
to time to engraftment and were excluded in the analyses to avoid bias from type of feeding 
modality. A total of 72 patients were included in the analysis. Institutional review board 
approval was obtained for conducting this study, and informed consent was required from all 
patients. Eligible patients were undergoing HSCT, English speaking, and 18 years or older. 
Non–English-speaking patients, those who received PN at any time from transplant to 
engraftment, and nonconsenting patients were excluded.
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Dietary Intake
Dietary intake was assessed using calorie counts to determine the amount of calories and 
protein patients consumed. Patients were visited after every meal, and a calorie count was 
conducted by a diet technician or a registered dietitian. Patients were given an informational 
sheet describing why they were placed on a calorie count as well as a worksheet to record 
any snacks consumed in between meals. Prior to the start of the study, to establish the 
consistency of dietary intake measures, a random sample of 10 meal trays from patients in 
the main hospital was assessed for caloric consumption by 11 raters (8 diet technicians, 2 
registered dietitians, and 1 dietetic intern). Raters calculated the number of calories 
consumed from each meal tray after estimating the amount of food consumed by the patient. 
Results using intraclass correlation (ICC) showed an ICC of 0.95, indicating good interrater 
agreement. Calorie counts began on the day patients received their transplantation (day 0) 
and continued until engraftment. After each meal, the percentage of each food item 
consumed at that meal was recorded and entered into the CBORD Foodservice Suite version 
6.8.100 (CBORD, Ithaca, NY), where the total calories and total protein were calculated for 
each meal. Snacks and nutrition supplements that patients consumed were also included. If a 
food item was not in CBORD Foodservice Suite, the caloric and protein information for the 
food item was obtained from the U.S. Department of Agriculture National Nutrient Database 
for Standard Reference version 1.2.2.6 If there were missing calorie counts, the research 
team used the electronic medical record to obtain the percentage of meals consumed from 
the nursing flow sheet. The research team then calculated that percentage of calories and 
protein from the average daily values of the 14-day menu cycle. If there was nothing 
recorded in the electronic medical record, the research team took an average of the other 2 
meals from that day to determine the calories and protein consumed for the missing meal as 
is standard practice at the medical center where the study took place. The total amount of 
calories and protein consumed per day was calculated from meals, snacks, and nutrition 
supplements. The percentage of caloric needs that were met for the study period was 
calculated as a proportion of net caloric intake (day of transplant to day of engraftment) 
divided by estimated caloric needs (30 kcal/kg/d and 1.5 g of protein/kg/d). If the patient’s 
admission weight was >120% of ideal body weight, adjusted body weight was used when 
calculating energy needs.7 For the purpose of this study, consuming ≥60% of caloric needs 
was considered adequate. Patients were divided into 2 groups: those who consumed ≥60% of 
their calorie needs and those who consumed <60% of their calorie needs.8
GI Symptoms
The MD Anderson Symptom Inventory–Gastrointestinal (MDASI-GI) was used to evaluate 
patients from the first day of transplant until engraftment. The MDASI-GI tool includes 13 
core items, 5 GI items, and 6 interference items and uses a 10 point rating scale for scoring.
9,10
 The MDASI-GI tool has been validated using a sample of autologous bone marrow 
transplant (BMT) patients.10 For the purpose of this study, a MDASI-GI component score 
was calculated using the 13 core items and 5 GI items. A MDASI-GI symptom score was 
also calculated and included 4 select core items (nausea, lack of appetite, dry mouth, and 
vomiting) and 4 select GI items (constipation, diarrhea, difficulty swallowing, and change in 
taste). These subset groupings are endorsed by the developers of the MDASI.10 The daily 
scores were averaged over the duration of the study (day 0 to engraftment) for each patient 
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and used in the analysis. Ratings for each individual symptom were also summed and 
averaged for each patient over the duration of the study.
Additional Variables
Additional data were collected to describe the study sample, including age, race, sex, body 
mass index (BMI, defined as kg/m2), HSCT type, and conditioning regimen.
Data Analysis
Nonparametric statistics were used to accommodate violations in the normality assumptions 
and differences in sample size for groups. Mann-Whitney U tests were used to determine 
differences in patient characteristics based on adequacy of oral intake (≥60% of caloric 
needs vs <60% of caloric needs). Spearman rank order correlation was used to determine the 
relationship between caloric intake and MDASI-GI component and individual GI symptom 
scores.
Results
Patient Characteristics
Table 1 summarizes the patient characteristics for all patients included in the analysis (n = 
72) and stratified by amount of calories consumed during the study. The study population 
was 65% white and 64% male with a mean ± SD age of 54.9 ± 11.8 years and median BMI 
of 28.0 (interquartile range [IQR], 24.4–32.3). Most patients received an autologous (72%) 
transplant compared with allogeneic (20%) and matched unrelated donor (MUD) (8%) 
transplants. This is consistent with the population of HSCT patients treated at the medical 
center where the study was conducted.
Dietary Intake
Total patients—Most patients consumed an oral diet without nutrition support (97.2%; n = 
70). Two patients (2.2%) received EN secondary to being intubated. The median (IQR) 
percentage of caloric needs met for all patients was 49.2% (35.1%–66.6%) (Table 2). Most 
patients (n = 50; 69.4%) consumed <60% of their caloric needs from the time of transplant 
to time of engraftment. Calories were also reported as kcal/kg/d. The median (IQR) intake 
for all subjects was 10.5 (7.0–14.8) kcal/kg/d, approximately one-third of their estimated 
needs (Table 2). As with calories, protein was examined as the percentage of protein needs 
consumed and grams of protein/kg/d. The median (IQR) percentage of protein needs met for 
all patients was 38.3% (27.1%–53.0%), and the median (IQR) intake of protein for all 
patients was 0.4 (0.3–0.6) g of protein/kg/d. As seen in Figure 1, calorie intake decreased 
from baseline to transplant day 8 as severity of GI symptoms increased. Average calorie 
intake fell to below 60% of requirements by transplant day 3.
Type of HSCT and conditioning regimen—A comparison of caloric and protein intake 
in HSCT patients receiving different types of transplants is also shown in Table 2. Patients 
were stratified by type of transplant: autologous, allogeneic, and MUD. Allogeneic HSCT 
patients consumed a significantly higher percentage of their calorie (P = .005) and protein 
needs (P = .004) than did autologous HSCT patients (Table 2). There were no other 
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significant differences in median percentage of caloric needs or protein needs met between 
the other groups. A post hoc analysis of calorie and protein intake between conditioning 
regimens was performed, but there were no significant differences.
GI symptoms—There were no significant differences in median MDASI-GI component 
scores or MDASI-GI symptom scores between those who consumed adequate calories 
compared with those who consumed inadequate calories. However, patients who consumed 
≥60% of caloric needs had significantly lower median diarrhea scores (1.7; IQR, 0.7–2.7) 
compared with those who consumed <60% of caloric needs (2.7; IQR, 1.6–2.7; P < .05). 
When stratified by type of HSCT, this was no longer significant. An inverse relationship 
between percentage of caloric needs met by total patients and MDASI-GI component score 
(rs = −0.28, P = .019), MDASI-GI symptom score (rs = −0.26, P = .029), and lack of appetite 
score (rs = −0.35, P < .003) was observed.
Discussion
Since many of the side effects of treatment experienced by HSCT patients may impair their 
ability to consume an adequate amount of calories and protein, those who consumed <60% 
of their caloric needs were predicted to report more severe GI symptoms compared with 
those who were able to consume ≥60% of their caloric needs.
The amount of calories and protein that HSCT patients consume as reported in the literature 
varies and is limited. The caloric and protein intake for patients in this study was consistent 
with other reports in HSCT patients.11,12 In a study conducted by Szeluga et al,11 the 
researchers reported an average intake of 20–25 kcal/kg/d and 0.5–1.0 g of protein/kg/d. The 
larger intakes in the study by Szeluga et al are likely due to inclusion of patients receiving 
supplemental EN or PN. In the current study, 70 patients (97.2%) consumed an oral diet 
without any nutrition support. Patients in our study consumed an average of 1109.9 ± 501.7 
kcal/d and 44.3 ± 20.9 g of protein/d, which is greater than the intake reported for patients in 
a study conducted by Roberts et al.12 Patients in the oral diet group of the Roberts et al study 
consumed 951 ± 191 kcal/d and 36 ± 10 g of protein/d. However, 50% (n = 14) of the 
patients in their oral diet group received PN due to 10 consecutive days of oral intake <40% 
of nutrient needs. This may account for the lower intake in these patients and help explain 
the discrepancy in the results between the 2 studies. Differences in intake may also be due to 
differences in the study populations. Roberts et al included only patients with breast cancer 
receiving autologous HSCT, while the current study and Szeluga et al included patients with 
various diagnoses receiving both autologous and allogeneic HSCT.
Habschmidt et al13 recently conducted a study surveying registered dietitians who practice 
within the area of HSCT. The purpose of this study was to determine the current medical 
nutrition therapy (MNT) provided to adult patients undergoing HSCT and examine the 
current and desired role of dietitians in providing MNT to HSCT patients. Most survey 
respondents reported that oral intake was the main form of nutrition therapy used in HSCT 
patients as they identified barriers to nutrition support, including GI toxicities (38%), 
physician and medical staff agreement with care (30%), mucositis (13%), and a lack of 
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research data and protocols for practice (8%). Similarly, most patients who consented in the 
present study consumed an oral diet (82.4%; n = 70).
Our findings show that most HSCT patients consumed <60% of caloric and protein needs 
from time of transplant to time of engraftment. Many of the GI side effects experienced by 
HSCT patients may affect their ability to consume an adequate amount of calories and 
protein; however, little supportive evidence exists in the literature. A study conducted by 
Leistra et al14 investigated predictors for achieving protein and energy requirements on the 
fourth day of admission in undernourished hospitalized patients. Negative predictors for 
achieving energy and protein requirements included nausea (odds ratio [OR], 0.18; 95% 
confidence interval [CI], 0.06–0.53; P <.001) and patients having cancer (OR, 0.57; 95% CI, 
0.35–0.93; P < .001); nausea was commonly reported in the present study as well.
Calorie and protein intake also varied depending on the type of transplant the patients 
received. Allogeneic and MUD HSCT patients consumed more calories and protein than did 
autologous HSCT patients. Age was considered a contributing factor to this difference since 
autologous HSCT patients tend to be older than allogeneic and MUD HSCT patients.15 
However, age was not significantly different between autologous and allogeneic/MUD 
HSCT patients in this study. The small sample size of the current study could have 
influenced the findings. Limited information is available in the literature examining 
differences in caloric intake by type of HSCT and conditioning regimen received.
A number of factors may have affected the MDASI-GI scores, resulting in very few 
differences between intake groups. There was a high amount of missing data, which may 
have biased the results. Twenty-five patients (34.7%) had more than 10% of data missing, 
which demonstrates the burden on patients to complete daily surveys. It appeared that the 
number of missing surveys increased as symptom severity increased, and thus the scores 
may be underestimated. Patients who consumed ≥60% of caloric needs had less diarrhea 
than those who consumed <60% of caloric needs. Adequate nutrients help heal the 
endothelial lining of the GI tract, which promotes regrowth of the endothelial lining and 
could possibly be related to better oral intake.16 However, many people may self-restrict 
their oral intake when they are experiencing diarrhea with the belief that food will worsen 
the effect. This may explain why those patients in the current study who consumed <60% 
had more diarrhea. A study conducted by Mulder et al17 compared the number of days that 
autologous HSCT patients who received either PN or partial parenteral plus EN by tube 
feeding (PPN/EN) experienced diarrhea. The percentage of days with diarrhea was lower in 
the PPN/EN group (26.8 ± 16.8 days) compared with the PN group (53.6 ± 20.4 days) (P < .
005).
Our findings showed a significant inverse relationship between intake and MDASI-GI 
component, MDASI-GI symptom score, and lack of appetite scores, which was expected. As 
these symptom scores increased, oral intake decreased. However, the relationships were 
weak, indicating that very little of the variance in intake was explained by the GI symptoms.
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Limitations
Several limitations should be considered when deriving conclusions from this study. Due to 
the small sample size, particularly across types of transplants and conditioning regimens, 
there may not have been enough power to detect actual differences in outcomes measured. 
Another limitation of the current study is that nil per os (NPO) status was not documented. 
Therefore, if no oral intake was reported, this could have indicated that patients were either 
choosing not to eat or were unable to eat due to NPO status. Possible reasons patients could 
have been NPO include procedures, tests, or neutropenic enterocolitis. Finally, the fact that 
severity of GI symptoms was based on self-report is a limitation of the current study.
Conclusion
Most patients consumed <60% of their caloric needs from time of transplant to time of 
engraftment. An inverse relationship between percentage of caloric needs met and MDASI-
GI component score, MDASI-GI symptom score, and lack of appetite score was observed. 
There were few differences in self-reported GI symptoms between the groups, but those who 
consumed >60% of caloric needs had significantly lower median diarrhea scores. More 
research is needed to describe the oral intake of HSCT patients by type of transplant and 
type of conditioning regimen. If consuming an adequate amount of calories and protein can 
demonstrably reduce the frequency and severity of GI symptoms in HSCT patients and 
positively affect clinical outcomes, maximizing nutrient delivery via EN support may 
become an important part of treatment for these patients. There appears to be a gap in the 
literature with respect to adequacy of intake and clinical outcomes, survival, and quality of 
life in this population. Future research investigating the association between nutrition 
adequacy and outcomes would make a positive contribution to the field.
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Figure 1. 
Average MD Anderson Symptom Inventory–Gastrointestinal (MDASI-GI) scores and 
percentage of caloric needs consumed by hematopoietic stem cell transplant patients (n = 
72). Day 0 = day of transplant.
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Table 1
Characteristics of Patients Receiving HSCT
Characteristic
Total
(N = 72)
≥60% of Caloric Needs
(n = 22)
<60% of Caloric Needs
(n = 50)  P Value
Sex .59
 Male 46 (63.9) 14 (63.6) 32 (64.0)
 Female 26 (36.1) 8 (36.4) 18 (36.0)
Race .44
 White 47 (65.3) 14 (63.6) 33 (66.0)
 Black 16 (22.2) 4 (18.2) 12 (24.0)
 Asian 1 (1.4) 1 (4.5) 0
 Hispanic 8 (11.1) 3 (13.6) 5 (10.0)
Age, mean ± SD, y
 Total 54.9 ± 11.8 56.6 ± 8.7 54.1 ± 12.9 .42
 Autologous 55.7 ± 13.1 59.6 ± 10.4 54.6 ± 13.7 .25
 Allogeneic 51.9 ± 7.7 53.4 ± 4.5 50.0 ± 10.8 .44
 MUDa 54.7 ± 5.5 51.5 ± 2.1 56.3 ± 6.2 .37
BMI, median (IQR) 28.0 (24.4–32.3) 25.3 (23.5–31.5) 28.4 (25.2–33.4) .07
BMI category
.19a
 Underweight 0 0 0
 Normal 20 (27.8) 10 (45.5) 10 (20.0)
 Overweight 26 (36.1) 5 (22.7) 21 (42.0)
 Obesity grade I 15 (20.8) 5 (22.7) 10 (20.0)
 Obesity grade II 7 (9.7) 1 (4.5) 6 (12.0)
 Obesity grade III 4 (5.6) 1 (4.5) 3 (6.0)
Type of HSCT .07
 Autologous 52 (72.2) 12 (54.5) 40 (80.0)
 Allogeneic 14 (19.4) 8 (36.4) 6 (12.0)
 MUD 6 (8.3) 2 (9.1) 4 (8.0)
Diagnosis
 Multiple myeloma 30 (41.7) 10 (45.5) 20 (40.0)
.04b
 Lymphoma 26 (36.1) 3 (13.6) 23 (46.0)
 Acute leukemia 13 (18.1) 7 (31.8) 6 (12.0)
 Myelofibrosis 2 (2.8) 1 (4.5) 1 (2.0)
 CLL/SLL 1 (1.4) 1 (4.5) 0
Conditioning regimen
.015c
 Melphalan 29 (40.3) 10 (45.5) 19 (38.0)
 BEAM 17 (23.6) 1 (4.5) 16 (32.0)
 Fludarabine/melphalan 13 (18.1) 7 (31.8) 6 (12.0)
 BendaEAM 5 (6.9) 1 (4.5) 4 (8.0)
 Busulfan/fludarabine 4 (5.6) 3 (13.6) 1 (2.0)
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Characteristic
Total
(N = 72)
≥60% of Caloric Needs
(n = 22)
<60% of Caloric Needs
(n = 50)  P Value
 Total-body irradiationd 3 (4.2) 0 3 (6.0)
 Ara-C 1 (1.4) 0 1 (2.0)
Values are presented as number (%) unless otherwise indicated. BEAM, BCNU (carmustine), etoposide, Ara-C (cytarabine), and melphalan; 
BendaEAM, bendamustine, etoposide, cytarabine, and melphalan; BMI, body mass index; CLL/SLL, chronic lymphocytic leukemia/small 
lymphocytic lymphoma; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; MUD, matched unrelated donor.
aχ2 Analysis between normal, overweight, and obese; P > .05.
bχ2 Analysis between lymphoma, multiple myeloma, and acute leukemia; P < .05.
cχ2 Analysis between melphalan, BEAM, and fludarabine/melphalan; P < .05.
d
Total-body irradiation plus additional chemotherapy agents, including fluarabine, cytoxan, and/or cyclophosphamide.
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Table 2
Median (IQR) Calorie and Protein Intake Over Time in HSCT Patients by Type of 
Transplant.
Energy Protein
Type of HSCT
Percent Caloric
Needs kcal/kg/d
Caloric
Deficit/d
Percent Protein
Needs
Grams of
Protein/kg/d
Protein
Deficit/d
Total (N = 72) 49.2
(35.1 to 66.6)
10.5
(7.0 to 14.8)
−1098
(−1435 to −640)
38.3
(27.1 to 53.0)
0.4
(0.3 to 0.6)
−68.7
(−80.2 to −40.8)
Autologous (n = 52) 44.5
(30.8 to 56.6)a
13.4
(9.3 to 17.0)a
−1135
(−1462 to −813)a
34.9
(24.9 to 44.9)a
0.5
(0.4 to 0.7)a
−70.7
(−82.6 to −50.9)a
Allogeneic (n = 14) 66.5
(49.8 to 97.8)b
20.0
(14.9 to 29.3)b
−557
(−1168 to −53)b
55.9
(38.1 to 76.9)b
0.6
(0.3 to 1.2)b
−39.0
(−75.9 to −27.3)b
MUD (n = 6) 58.1
(46.4 to 65.1)
17.4
(13.9 to 19.5)
−1084
(−1267 to −920)
45.5
(40.5 to 60.4)
0.7
(0.6 to 0.9)
−68.9
(−73.5 to −51.9)
HSCT, hematopoietic stem cell transplant; IQR, interquartile range; MUD, matched unrelated donor.
aValues bearing different superscripts in the same column are significantly different on the basis of Bonferroni-corrected Mann-Whitney U tests.
bValues bearing different superscripts in the same column are significantly different on the basis of Bonferroni-corrected Mann-Whitney U tests.
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